SMS Pharmaceuticals reported an 18% increase in revenue and a 20% rise in PAT for Q2 FY25 compared to the previous year, driven by strong demand in its product portfolio, with EBITDA margin stable at 16%. The company is on track with its capital investments and growth outlook for FY25.